Clinical trials: Cryptogenic Ischemic Stroke
Syncope, Cryptogenic Stroke
ConfirmRxTM: Posture and Activity
Insertable Cardiac Monitor's (ICM's) such as Confirm Rx™ are leadless devices implanted for long-term heart rhythm monitoring in the diagnosis and management of clinical conditions such as recurrent unexplained syncope…
- Trial name
- NCT03803969
- Testing
- ConfirmRx (Insertable Cardiac Monitor)
- Where
- 8 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Patent Foramen Ovale, Cryptogenic Stroke
Comparison of Lower vs Upper Extremity Injection Agitated Saline to Identify Patent Foramen Ovale With Echocardiography
Study Title LOwer vs upper extremity injection agitated saline for identifiCation of pATent foramen ovalE (LOCATE) Pilot study to determine safety of lower extremity injection of agitated saline for echocardiography of the heart.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Embolic Infarction
- Trial name
- LOCATE (NCT07009678)
- Testing
- intravenous access in greater saphenous vein compared to upper extremity site.
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. John's Hospital
Cryptogenic Stroke, Atrial Fibrillation
Incidence and Predictors of Recurrent Stroke in Cryptogenic Stroke Patients With Atrial Fibrillation
Brief Summary: This study aimed to investigate the risk and factors that predict recurrent stroke in patients who initially had a stroke with no clear cause (called cryptogenic stroke) and were later found to have atrial…
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Recurrent Ischemic Stroke
- Trial name
- NCT07126184
- Testing
- Extended Cardiac Monitoring
- Where
- Pakistan
- Volunteers
- 109 people
- Sponsor
- Nangarhar University
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
PFO, PFO - Patent Foramen Ovale
Evaluating Percutaneous Repair Of The Atrial Septum With A Novel PFO Occluder: The PROTEA-PFO OUS Study
The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a…
- Conditions
- PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale
- Trial name
- PROTEA-PFO OUS (NCT07698951)
- Testing
- Recross P3 Occluder (P3O) System
- Where
- Serbia
- Volunteers
- 15 people
- Sponsor
- Recross Cardio, Inc.
Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder
Atrial Anomalies Predict Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Cryptogenic Stroke
Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients.
- Conditions
- Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder, Left Atrial Dilatation, Cryptogenic Stroke
- Trial name
- CRIPTO-FAST (NCT06542770)
- Testing
- Early implant of cardiac monitor
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Parc de Salut Mar
Cryptogenic Stroke, High Risk Patent Foramen Ovale
Evaluation of Prevalence and Clinical Impact of Atrial Fibrillation in Elderly Patients With Cryptogenic Stroke and High-Risk Patent Foramen Ovale
The purpose of DEFENSE-ELDERLY is to identify the prevalence of AF and evaluate the clinical impact of AF in elderly ESUS patients and no other known sources of stroke besides a high-risk patent foramen ovale, and compare it with…
- Trial name
- DefenseElderly (NCT04285918)
- Testing
- Percutaneous device closure
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
Occult Cancer
Intensive Cancer Screening After Cryptogenic Stroke
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening…
- Trial name
- INCOGNITO (NCT05733416)
- Testing
- FDG PET/CT, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Ottawa Hospital Research Institute
Patent Foramen Ovale (PFO)
Non-Invasive Detection of Right-to-Left Cardiac Shunts
This study will test the sensitivity of a novel, battery-powered, non-invasive ultrasound device to detect a right-to-left shunt
- Trial name
- HEADBAND (NCT07420400)
- Testing
- Point-of-care ultrasound
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Scripps Health
Cryptogenic Stroke
Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence
This is a multi-center retrospective analysis of consecutive adult patients with cryptogenic stroke patients following a comprehensive workup for the underlying stroke etiology.
- Trial name
- CASPR (NCT06398366)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- The Cooper Health System
Patent Foramen Ovale
Internal Microstructure of Patent Foramen Ovale Related to Stroke
This study aims to (1) investigate the internal microstructure of patent foramen ovale related to cryptogenic stroke, transient ischemic attack or migraine and determine the effectiveness of transcatheter closure in these…
- Trial name
- IMPORT (NCT04686253)
- Testing
- not appliable
- Where
- 2 sites in China
- Volunteers
- 1,200 people
- Sponsor
- China National Center for Cardiovascular Diseases
Patent Foramen Ovale
Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO)
Background and hypothesis: The appropriate treatment strategy for secondary stroke prevention in patients with cryptogenic stroke and patent foramen ovale (PFO) remains challenging.
- Trial name
- NCT01550588
- Testing
- Device closure, Standard medical treatment
- Where
- 4 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- Jae-Kwan Song
Patent Foramen Ovale, Cryptogenic Stroke
Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry)
Patent foramen ovale (PFO) is a congenital interatrial communication present in about one quarter of the general population and is recognized as a major cause of cryptogenic stroke.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Transient Ischemic Attack Due to Embolism, Atrial Fibrillation
- Trial name
- NCT07724171
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
Cryptogenic Stroke, Atrial Fibrillation
Early Detection of Atrial Fibrillation Using Mobile Technology in Cryptogenic Stroke Patients
The purpose of this study is to demonstrate the added value of mobile health (mHealth) to detect atrial fibrillation (AF) early in the care path of cryptogenic stroke and transient ischemic attack (TIA) patients.
- Trial name
- REMOTE (NCT05006105)
- Testing
- seven-day ECG Holter, 24-hour blood pressure monitor, Questionnaire: vision of mHealth
- Where
- 2 sites in Belgium
- Volunteers
- 225 people
- Sponsor
- Ziekenhuis Oost-Limburg
Stroke
Left Atrial Function in Recurrent Stroke of Unknown Cause
Stroke is an important cause of disability and the third leading cause of death. Approximately 30 to 40 % of all strokes are estimated to be cryptogenic (i.e. no cause can be found).
- Trial name
- NCT02968329
- Where
- Belgium
- Volunteers
- 500 people
- Sponsor
- Hasselt University
Cryptogenic Stroke
Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent…
- Trial name
- NCT00465270
- Testing
- AMPLATZER PFO Occluder, Standard of Care - Medical Management
- Where
- 69 sites in United States, Canada
- Volunteers
- 980 people
- Sponsor
- Abbott Medical Devices
Immune Thrombocytopenia (ITP), Acute Ischemic Stroke
Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by immune-related platelet destruction and impaired platelet production.
- Trial name
- NCT07070193
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Ischemic Stroke, Cryptogenic, Transient Ischemic Attack
Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke
Scientific Background: In secondary prevention of ischemic stroke, detection of atrial fibrillation (AFib) and subsequent anticoagulation therapy reduce the risk of recurrent stroke by approximately 60%.
- Conditions
- Ischemic Stroke, Cryptogenic, Transient Ischemic Attack, Atrial Fibrillation
- Trial name
- WATCH AFib (NCT06005233)
- Testing
- Smartwatch
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Technical University of Munich
Patent Foramen Ovale, Cryptogenic Stroke
Encore PFO Closure Device - The PerFOrm Trial
The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.
- Trial name
- NCT05537753
- Testing
- Encore PFO closure device, FDA-approved PFO closure device
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Encore Medical Inc.